Genedrive PLC genedrive plc awarded Innovate UK grant (0378X)
November 21 2017 - 2:01AM
UK Regulatory
TIDMGDR
RNS Number : 0378X
Genedrive PLC
21 November 2017
For release: 21 November 2017
genedrive plc ("genedrive" or the "Company")
genedrive plc awarded GBP600,000 Innovate UK grant
Award to support the development of a centrifuge-free plasma
separation consumable for its Genedrive(R) HCV assay
genedrive plc, the near patient molecular diagnostics company,
today announces it has now been formally awarded an Innovate UK
grant for the development of a disposable centrifuge-free plasma
separation consumable device. In its preliminary results issued in
October, genedrive confirmed it had been conditionally offered this
grant. The device is planned to support the future use of
genedrive's HCV ID Kit closer to a point of care setting. genedrive
plc and its collaborators, NHS Tayside and the Univeristy of
Dundee, will receive circa GBP600,000 of which genedrive will
account for its GBP484,000 share of the funding as income, matched
to costs incurred over the periods to 30 June 2018 and 2019.
David Budd, Chief Executive Officer of genedrive plc said: "This
has the opportunity to be a very novel and impactful project and we
are delighted that Innovate UK has chosen to support us. This
device will aim to improve the applicability of the Genedrive(R)
HCV assay for closer to patient settings and would be a significant
step forward in positioning the test for true decentralised
diagnostics. Further, the device is anticipated to be independent
from the Genedrive(R) platform, opening the opportunity for other
diagnostic instruments that need plasma as a starting point for
blood borne viral testing."
Genedrive(R) HCV ID Kit is performed on the Company's
Genedrive(R) portable molecular diagnostics platform, designed for
use at the point of need. The assay uses only a small amount of
human plasma (25ul), eliminating the need for a separate RNA viral
extraction process, and yields results within 90 minutes. genedrive
has distribution agreements with subsidiaries of Sysmex Corporation
for the distribution of the Genedrive(R) platform in the EMEA and
Asia Pacific regions.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF assay has been
launched in India and a Genedrive(R) HCV test has received CE-IVD
Certification and has been launched in Africa. genedrive has
distribution agreements with subsidiaries of Sysmex Corporation for
the distribution of the Genedrive(R) platform in the EMEA and Asia
Pacific regions.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Innovate UK
Innovate UK is the UK's innovation agency. It works with people,
companies and partner organisations to find and drive the science
and technology innovations that will grow the UK economy.
For further information visit www.innovateuk.gov.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFEMEFSFWSEEF
(END) Dow Jones Newswires
November 21, 2017 02:01 ET (07:01 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024